Abstract Ovarian and uterine carcinosarcoma (CS) are characterized by their aggressive clinical behavior and poor prognosis. We evaluated the efficacy of trastuzumab-emtansine (T-DM1), against primary HER2 positive and HER2 negative CS cell lines in vitro and in vivo. Eight primary CS cell lines were evaluated for HER2 amplification and protein expression by fluorescence in situ hybridization, immunohistochemistry, flow cytometry and qRT-PCR. Sensitivity to T-DM1-induced antibody-dependent-cell-mediated-cytotoxicity (ADCC) was evaluated in 4-h-chromium-releaseassays. T-DM1 cytostatic and apoptotic activities were evaluated using flow cytometry based proliferation assays. In vivo activity of T-DM1 was also evaluated. HER2 protein overexpression and gene amplification were detected in 25 % (2/8) of the primary CS cell lines. T-DM1 and T were similarly effective in inducing strong ADCC against CS overexpressing HER2 at 3? levels. In contrast, T-DM1 was dramatically more effective than T in inhibiting cell proliferation (P \ 0.0001) and in inducing G2/M phase cell cycle arrest in the HER2 expressing cell lines (shift of G2/M: mean ± SEM from 14.87 ± 1.23 to 66.57 ± 4.56 %, P \ 0.0001). Importantly, T-DM1 was highly active at reducing tumor formation in vivo in CS xenografts overexpressing HER2 (P = 0.0001 and P \ 0.0001 compared to T and vehicle respectively) with a significantly longer survival when compared to T and vehicle mice (P = 0.008 and P = 0.0001 respectively). T-DM1 may represent a novel treatment option for the subset of HER2 positive CS patients with disease refractory to chemotherapy.
Introduction
Carcinosarcoma (CS), also known as malignant mixed Müllerian tumors (MMMT) comprises one of the most rare and challenging tumors among all gynecological malignancies. CS are composed of a mixture of carcinomatous (malignant epithelial) and sarcomatous (mesenchymal) elements. The epithelial component is usually serous, but may also be endometrioid, clear cell, squamous cell or undifferentiated carcinoma. The sarcomatous component can be homologous (tissue native to the primary site) or heterologous (tissue not native to the primary site) [1] . These tumors can arise in any organ of the female genital tract such as endometrium, ovary, cervix, vulva, vagina or fallopian tube. The endometrium is the most common primary site.
Overall, uterine sarcoma accounts for 3-5 % of all corpus uteri malignancies with an incidence in the United States of 1-4 per 100,000 women [2] . Surgical debulking is the mainstay of treatment, but the high rate of tumor recurrence (40-60 %) and the poor median survival of 16-40 months after diagnosis suggest a need to identify more effective treatment modalities [3, 4] . CS arising from the ovary may account for only 1-4 % of all ovarian cancers with most individuals diagnosed with advanced stage (i.e., III or IV) disease at the time of surgical staging [5, 6] . Ovarian CS has a worse prognosis than uterine CS, with a median survival rate of 8-32 months and recurrence rates of 50-100 % [4, 7] .
The pathogenesis and genetic alterations of CS remain unclear and different theories have been proposed to explain the biphasic nature of these tumors [8, 9] . Multiple studies have linked the clinically aggressive behavior of CS to the epithelial component of the tumor and consistent with this view, CS has been recently reclassified as metaplastic carcinomas [10, 11] . Because the carcinomatous component drives the biphasic tumor growth, it is speculated that therapeutic interventions targeting cellular pathways that drive epithelial cell proliferation may potentially be beneficial against these biologically aggressive tumors.
The Human Epidermal Growth Factor family of receptors (ErbB family) includes four structurally related members: HER1 (ErbB1, also known as EGFR), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). The ErbB family members are receptor tyrosine kinases (RTKs) with an analogous structure, consisting of an extracellular ligandbinding domain, a single hydrophobic transmembrane region and an intracellular segment that contains a conserved tyrosine kinase domain [12] . HER2 is known to play a pivotal role in cell growth, survival and differentiation in normal and tumor cells by enhancing kinase-mediated activation of downstream signaling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositide 3-kinase [13, 14] . The HER2/neu oncogene has been reported as overexpressed and/or amplified in various human tumor types including CS of the female genital tract [15] [16] [17] [18] [19] [20] [21] [22] . HER2 overexpressing cancers have been associated with worse prognosis when compared with matched HER2 non-amplified cancers, including higher mortality in early-stage disease, reduced time to relapse and a higher incidence of metastases [23, 24] .
Trastuzumab emtansine (T-DM1, Kadcyla TM , Genentech, South San Francisco, CA) is a novel HER2-targeting immunotoxin developed by conjugation of Trastuzumab (T) (Herceptin, Genentech, South San Francisco, CA) with maytansinoid cytotoxin (DM1), a highly potent microtubule polymerization inhibitor [25] . T-DM1 is internalized upon binding to the extracellular sub-domain IV of the HER2 receptor. After lysosomal degradation, DM1 is released in the cytoplasm, leading to cell cycle arrest and apoptotic cell death [26] . Our group has recently identified HER2 as a potential target in CS raising the possibility that anti-HER2 therapies may be a viable treatment options in these settings [27] . This study represents the first evaluation of the activity of T-DM1 against HER2 positive and negative primary CS cell lines in vitro followed by developing a supportive CS in vivo model.
Methods

Establishment of carcinosarcoma cell lines
Study approval was obtained from the Institutional Review Board, and all patients signed consent prior to tissue collection according to the institutional guidelines. A total of eight primary uterine and ovarian CS cell lines were established from fresh tumor biopsy samples, as described previously [27] . Tumors were staged according to the International Federation of Gynecology and Obstetrics staging system. Patient characteristics are noted in Table 1 .
Immunostaining of tissue and cell blocks of primary carcinosarcoma Tumor blocks and cell blocks were obtained from all CS cell line patients and reviewed by a gynecologic surgical pathologist. The level of HER2 expression was then evaluated as previously described [17] . HER2 staining intensity was graded on the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) 2007 breast scoring criteria: 0 (negative = no staining observed), 1 ? (light staining = weak, incomplete membrane staining in any proportion of tumor cells or weak complete membrane staining in \10 % of tumor cells), 2 ? (moderate staining = weak complete membrane staining in at least 10 % of tumor cells or intense complete membrane staining in 30 % or less of tumor cells), or 3 ? (strong staining = uniform, intense membrane staining in [30 % of tumor cells) [28] . Appropriate positive and negative controls were used with each case.
Fluorescence in situ hybridization of cell blocks from primary CS Fluorescence in situ hybridization (FISH) analysis was performed using the PathVysion HER2 DNA-FISH-Kit (Abbott Molecular Inc., Abbott Park, IL, USA) according to the manufacturer's instructions and as previously described [27] . Fluorescent signals in at least 30 nonoverlapping interphase nuclei with intact morphology were scored using an Olympus BX61 microscope (Olympus America Inc.) with a 60-x planar objective, using the filter that permits simultaneous green and red colors. Tumor cells were scored for the number of orange (HER2/neu) and green (CEP17) signals. HER2/neu amplification was defined by a HER2/neu/CEP17 copy ratio C2.0
Quantitative real-time polymerase chain reaction (qRT-PCR)
RNA extraction from all carcinosarcoma cell lines and from normal control tissue was performed using AllPrep DNA/ RNA/Protein Mini Kit (Qiagen, Germantown, MD) according to the manufacturer's instructions. Total RNA (5 lg) was reverse-transcribed using Superscript III (Invit- , was used to normalize variations in cDNA quantities from different samples. The comparative threshold cycle (Ct) method was used for the calculation of amplification fold as specified by the manufacturer and previously described [27] . Analyses were performed using SDS software 2.2.2 (Applied Biosystems/Life Technologies).
Flow cytometry assay for HER2 staining Trastuzumab (Herceptin, Genentech, South San Francisco, CA), a humanized monoclonal antibody (mAb) of the IgG1 isotype that binds with high affinity to the extracellular domain of the HER2 receptor was used to assess HER2 expression on the surface of tumor cells. All the primary carcinosarcoma cell lines were incubated with 2.5 lg/ml of trastuzumab for 30 min on ice. Rituximab (Rituxan, Genentech, South San Francisco, CA), a chimeric anti-CD20 monoclonal-antibody (mAb) was used as a negative control (2.5 lg/ml). A fluorescein isothiocyanate-conjugated Goat F(ab')2 Anti-human immunoglobulin was used as a secondary reagent (Invitrogen, Life Technologies). Analysis was conducted with a FACScalibur, using Cell Quest software (BD Biosciences, San Diego, CA, USA).
Test for antibody-dependant cell-mediated cytotoxicity (ADCC)
Standard 4-h chromium ( 51 Cr) release assay was performed to measure the cytotoxic reactivity of Ficoll-Hypaqueseparated peripheral blood lymphocytes (PBLs) from several healthy donors, in combination with T-DM1 or trastuzumab against the CS target cell lines at effector to target ratios (E:T) of 10:1 and 20:1. The release of 51 Cr from target cells was measured as evidence of tumor cell lysis after exposure of the tumor cells to 2.5 lg/ml of T-DM1 or 2.5 lg/ml of T. Concentration-response experiments were performed in order to determine the optimal antibody dosing for ADCC experiments. The negative control condition was the incubation of target cells alone. As a positive control condition, 1 % sodium dodecyl sulfate (SDS) was used to achieve complete lysis of target cells. Chimeric anti-CD20 mAb rituximab 2.5 lg/ml was used as the negative control for T-DM1 and T in all bioassays. Briefly, the cells were 51 Cr-labelled for 1 h, washed, incubated with the antibodies and the release of 51 Cr in the supernatant was analyzed after 4 h. 51 Cr-released from the target cells by cytolysis was counted in gamma radiation counter (2470 WIZARD 2 Automatic Gamma Counter, PerkinElmer). The percentage cytotoxicity of trastuzumab or T-DM1 was calculated by the following formula: % cytotoxicity = 100 9 (E-S)/(T-S), where E is the experimental release, S is the spontaneous release by target cells, T is the maximum release by target cells lysed with 1 % SDS. Results are mean ± SEM (standard error of mean).
Proliferation assay CS cell lines were plated at log phase of growth in 6-well tissue culture plates at a density of 50,000-80,000 cells in RPMI 1640 media (Life Technologies, Carlsbad, CA) supplemented with 10 % fetal bovine serum, 1 % penicillin/streptomycin (Mediatech, Manassas, VA), and 0.3 % fungizone (Life Technologies, Carlsbad, CA). After 24 h incubation, cells were treated with T-DM1, T and rituximab at the saturating concentration of 2, 20 and 20 lg/ml respectively, determined by previously conducted concentration-response experiments. 72 h after drugs treatment cells were harvested in their entirety, centrifuged and stained with propidium iodide (2 ll of 500 lg/ml stock solution in PBS). Analysis was performed using flow cytometry based assay to quantify percent viable cells as a mean ± SEM relative to untreated cells as 100 % viable controls. A minimum of 3 independent experiments per cell line were performed.
Cell cycle analysis of CS cell lines after exposure to T-DM1 by flow cytometry CS cell lines were plated in six-well tissue culture plates and when in exponential growth treated with T-DM1 at concentration of 2 lg/ml or with control mAbs (T and rituximab, 20 lg/ml). After 24-48 h of treatment cells were harvested, fixed with 70 % ethanol for at least 30 min, then washed and stained with 50 lg/ml of propidium iodide (PI) in the presence of 100 lg/ml of ribonuclease A. Quantification of cell cycle distribution was determined by flow cytometric analysis of propidium iodide fluorescence using the FACScalibur and Cell Quest software with doublet discrimination. For each analysis 10,000 gated events were collected and data analysis was performed using Cell Quest and FlowJo v8.8.2. Results are mean ± SEM.
In vivo treatment
Six to eight week-old C.B-17/SCID mice were given a single subcutaneous injection of 7 9 10 6 CS SARARK-6 cells (HER2/neu amplified) in approximately 200 lL of a 1:1 solution of sterile PBS containing cells and Matrigel (BD Biosciences). Once the mean tumor volume was 0.15 cm 3 , the mice were randomized into 3 treatment groups. Each group consisted of 5 mice and injections with the treatment drugs were administered after an 8-day period to allow tumor establishment. The mice were randomized to receive T-DM1 (15 mg/kg), trastuzumab (15 mg/kg), or vehicle sterile water. Drug dosages were chosen accordingly to previous studies conducted on different xenograft models [26, 29, 30] . All treatment drugs were given as an intravenous (IV) injection once per week. The mice in each group were given series of 5 injections after which they were placed in follow-up and observed for overall survival as the primary outcome measure. Tumor measurements and mouse weights were recorded twice weekly. Mice were sacrificed if tumors reached 1 cm 3 using the formula (width) 2 9 height/2. Animal care and euthanasia was carried out according to the rules and regulations as set forth by the Institutional Animal Care and Use Committee (IACUC).
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 6 (GraphPad Software, Inc. San Diego, CA). For quantitative real-time PCR (qRT-PCR) data, right skewing was removed by taking copy number ratios relative to the lowest-expressing normal endometrium (NEC) or normal ovarian sample (NOVA) (relative copy number), and then log 2 transforming them to DCt values. A Wilcoxon ranksum test was used to compare CS cell lines to normal endometrium or ovary for differences in immunohistochemistry (IHC) staining intensity. A two-tailed unpaired t test was used to evaluate the differences in HER2 expression by flow cytometry. The differences in ADCC levels by 4-h chromium release assays as well as the inhibition of proliferation in the CS cell lines after exposure to T versus T-DM1 and cell cycle changes in the HER2 overexpressing and not overexpressing cell lines were evaluated by the two-tailed unpaired student t-test. Overall survival data were analyzed and plotted using the Kaplan-Meier method. Survival curves were compared using the log-rank test. Differences in all comparisons were considered statistically significant at P values \0.05.
Results
HER2 expression by IHC in primary uterine and ovarian CS cell lines
Immunohistochemical analysis of HER2 expression was performed on tissue and cell blocks of all primary uterine and ovarian CS patients available to this study. High levels of HER2 protein expression were detected in 2 out of 8 of the CS cell lines tested. Specifically, SARARK-6 and SARARK-9 showed strong (3?) HER2 positivity. In contrast, negligible HER2 expression (i.e., 0/1?) was detected in SARARK-1, SARARK-3, SARARK-4, SAR-ARK-7, SARARK-8 and SARARK-10 ( Table 2 ). The cell lines SARARK-6 and SARARK-1 were therefore chosen as representative cell lines for the next set of experiments because of their differential HER2 expression and their similar growth rates (data not shown).
ErbB2 gene amplification by FISH
Fluorescence in situ hybridization (FISH) was performed on 6 out of the 8 cell blocks obtained from the primary cell lines tested in this study. ErbB2 gene amplification was detected in both primary CS cell lines found to overexpress HER2 at 3? level by IHC (i.e., SARARK-6 and SARARK-9 cells, Table 2 ). In contrast, all CS cell lines tested by IHC and found negative for HER2 protein overexpression were also found not amplified in the FISH assays (Table 2) . 
HER2 expression by qRT-PCR in CS cell lines
Ovarian and uterine CS cell lines grown as primary cultures were tested by qRT-PCR to evaluate HER2 receptor expression at the mRNA level (i.e., mRNA copy number). Negative controls were normal endometrium and ovarian tissues. The HER2 mRNA levels in the high expressing cell lines were significantly higher compared to normal control tissue. The mRNA copy number for SARARK-6 and SA-RAK-9 (HER2 overexpressing cell lines) was 5634.2, and 897.64 respectively. This HER2 expression was significantly higher when compared with mRNA copy numbers from the low HER2 expressing cell lines SARARK-1, SARARK-3, SARARK-4, SARARK-7, SARARK-8 and SARARK-10 (range from 10.9 to 75.06) (P \ 0.01) ( Table 2 ).
HER2 expression by flow cytometry
To assess the possibility to target HER2 also in CS cells, its expression on cell surface was evaluated on live cells by flow cytometry. HER2 expression was in good agreement with the expression results found by qRT-PCR and IHC in all cell lines. In this regard, very high expression levels of HER2 were found in both SARARK-6 and SARARK-9 cell lines that 
ADCC mediated by T-DM1 and T in carcinosarcoma cell lines
To address whether or not conjugation to DM1 effected the ability of trastuzumab to cause ADCC, CS cell lines were tested for their sensitivity to NK-mediated cytotoxicity after exposure to heterologous PBLs collected from several healthy donors in standard 4 h 51 Cr release assays. CS cells were found to be resistant to PBL-mediated cytotoxicity when exposed to PBLs with or without rituximab control antibody as effectors (2.5 lg/ml) at E:T ratios of 10:1 and 20:1 (mean killing ± SEM of 2.1 ± 1.7 % with PBLs alone and mean ± SEM of 3.5 ± 1.4 % in the presence of PBLs ? rituximab at the highest concentration). Next we exposed CS cells to heterologous PBLs in the presence of T-DM1 (2.5 lg/ml) and T (2.5 lg/ml). We found both antibodies to be similarly effective in inducing strong ADCC against the high HER2 expressing cell line (SAR-ARK-6) with mean cytotoxicity ± SEM of 68 ± 5 versus 63 ± 6 % of T-DM1 versus T (P = 0.259) (Fig. 2) . Negligible ADCC was detected against cell lines with low/ negative HER2 expression when combined with PBLs and T-DM1 or T compared to control (data not shown).
T-DM1 is more effective than T at inhibiting CS cell proliferation T-DM1 was dramatically more effective than T in inhibiting HER2 overexpressing cell proliferation and in causing cell death as determined by flow cytometry and propidium iodide uptake. Figure 3 shows representative experimental results for SARARK-6 (i.e., a CS with high HER2 expression) after T and T-DM1 exposure. We found a mean number of viable 
Effects of T-DM1 on cell cycle progression
In order to determine T-DM1's effect on the cell cycle, cells were exposed to T-DM1 for 24 or 48 h and DNA was stained with propidium iodide for quantification of the different cell cycle phases. Exposure to T-DM1 resulted in a concentration-dependent increase in G2/M phase cells in all CS cell lines according with their HER2 expression levels (data not shown). We found a dramatic G2/M phase shift in the high HER2 expressing cell line (i.e., SARARK-6) from a mean ± SEM of 14.87 ± 1.23 % in the untreated sample to a mean of 66.57 ± 4.56 % after exposure to 2 lg/ml of T-DM1, as would be predicted by a drug that disrupts microtubule function (P \ 0.0001) (Fig. 4) . In contrast, no significant G2/M phase arrest was noted in the low HER2 expressing cell line (i.e., SARARK-1) after T-DM1 treatment with a shift from a mean ± SEM of 12.70 ± 3.37 % to a mean of 15.81 ± 3.07 % (P = 0.8) (Fig. 4) . We also analyzed the effect of T in the same cell lines with a nonsignificant G2/M phase perturbation [mean ± SEM of 14.87 ± 1.23 % to a mean of 17.3 ± 0.75 % (P = 0.2) for SARARK-6; mean ± SEM of 12.70 ± 3.37 % to a mean of 8.87 ± 2.24 % (P = 0.4) for SARARK-1].
In-vivo therapeutic efficacy of T and T-DM1 in HER2 overexpressed CS xenografts An in vivo experiment was used to determine the effect of T and T-DM1 on inhibition of tumor growth. Tumors were clearly visible in all mice inoculated with a mean volume of 0.15 cm 3 before starting the drug treatment. Mice treated with T-DM1 achieved a grossly complete response when compared to T and vehicle group (P = 0.0001 and P \ 0.0001 respectively) (Fig. 5a) . Indeed, all animals treated with T-DM-1 (i.e., 5 out of 5) remained free of detectable tumor for the entire duration of the study period (i.e., over 90 days) with a ***P value of P = 0.008 and P = 0.0001 when compared to T and vehicle group respectively (Fig. 5b) . In contrast, all mice of the trastuzumab group required euthanasia or died from tumor burden between days 3 and 31 after suspension of trastuzumab injection. All mice in the vehicle group (n = 5) had to be euthanized because of tumor burden between days 17-38 after tumor injection. Importantly, mice's body weight was not affected (data not shown) and no signs of general toxicity were seen in any of the 3 treatment groups.
Discussion
CS of the female genital tract are rare tumors characterized by aggressive clinical behavior. Although surgical debulking remains the mainstay of treatment, there continues to be the need for new effective adjuvant therapies given the high rate of tumor recurrence and poor survival in women diagnosed with CS [3, 4] . In the last few years, novel immunotherapeutic approaches using fully human anti-HER2 antibody-drug conjugates (ADCs) are increasingly being evaluated as targeted therapies for achieving clinically significant levels of cell killing against HER2 overexpressing tumors while minimizing damage to healthy tissues.
Consistent with this view, multiple groups including our own, have investigated the expression levels of HER2 in uterine and ovarian CS [19] [20] [21] [22] 27] [19] . Our results evaluating HER2 expression in primary CS cell lines recently established in our laboratory are consistent with the previously reported results [19] . Indeed, we found ErbB2 to be amplified by FISH in 2 of 8 (25 %) of uterine and ovarian CS cell lines available for study. We also evaluated and compared HER2 positivity in primary CS cell lines by real-time PCR as well as by flow cytometry. We found a significant correlation between the high mRNA copy numbers with the high surface protein expression by IHC (i.e., 3?) and flow cytometry. While the identification of CS overexpressing HER2 at 3? level by IHC and/or harboring amplification of the ErbB2 gene by FISH may potentially represent the most effective way to guide selection of CS patients who may benefit more from T-DM1 therapy, demonstration of the contribution of HER2 protein expression and gene amplification to the sensitivity of a tumor to a specific targeted agent such as T-DM1 requires functional in vitro and in vivo validation. Previous studies have reported very little activity of a dose of unconjugated DM1 that was equivalent to the amount of DM1 conjugated to trastuzumab or to an aspecific antibody [26, 31] .
Our experiments consistently demonstrate that T-DM1 has a strong growth inhibitory effect on HER2 positive CS cell lines in vitro as well as in vivo in SCID mice harboring CS xenografts. While both T-DM1 and T evoked similar ADCC against HER2 overexpressing CS cell lines in the presence of allogeneic PBLs, T-DM1 was found to be dramatically more effective than T in inhibiting cell proliferation and in inducing cell death after G2/M phase cell cycle arrest in the absence of mononuclear cells. Importantly, while both HER2 3? CS cell lines were found to be resistant to the cytostatic effect of T they remained highly sensitive to the exposure to T-DM1.
Trastuzumab emtansine combines two mechanisms of action: (a) Trastuzumab binds selectively to the HER2 positive tumor cells and blocks the uncontrolled signals that contribute to the growth and survival of the tumor and recruits natural killer (NK) cells for the initiation of ADCC; (b) the DM1 (mertansine) is released within the cells and cause apoptosis by blocking cell duplication [31] . Because T-DM1 targets only cancer cells overexpressing HER2, exposure of healthy cells to DM1 is minimized. T-DM1 is the first ADC to receive full approval from the United States Food and Drug Administration (FDA) on the basis of the findings of EMILIA, a randomized phase III trial to assess the efficacy and safety of T-DM1 versus lapatinib plus capecitabine in patients with HER2 positive advanced breast cancer who received prior Herceptin and a taxane. In this study a total of 991 patients were treated with a median progression-free survival of 9.6 months in the T-DM1 arm compared with 6.4 months in the lapatinib/capecitabine arm and a Hazard Ratio for progression or death of 0.65 in favor of T-DM1 (P \ 0.001). Patients treated with T-DM1 showed a significantly higher objective response rate (ORR) of 43.6 % compared with 30.8 % in the lapatinib/capecitabine group (P \ 0.001), with significantly longer overall survival [32] . Overall T-DM1 appears to be safer than the lapatinib/capecitabine combination and well tolerated as a single agent given at 3.6 mg/kg every 3 weeks. This dosing differs from the 6 mg/kg every 3 weeks T dosing. Moreover T-DM1 has a shorter half-life than T (approximately 4 days for T-DM1 versus 3-4 weeks for T), which may also result in a decrease in adverse effects including cardiotoxicity associated with T [33] .
In conclusion, this is the first report that explores the potential activity of T-DM1 therapy in HER2 overexpressing primary CS cell lines. Our in vitro and in vivo experiments suggest that T-DM1 and T are similarly effective in inducing strong ADCC against primary HER2 positive CS cell lines in the presence of PBLs. In contrast, our in vitro experimental results in the absence of PBLs clearly demonstrate that T-DM1 is considerably more effective than T in inhibiting cell proliferation and in inducing G2/M phase cell cycle arrest due to the action of the DM1 toxin. Importantly, our in vitro findings were confirmed in a relevant in vivo model of primary CS xenograft overexpressing HER2 at 3? levels and demonstrating HER2 gene amplification, where complete tumor regression was achieved in all T-DM1 treated mice.
Due to the significant fraction of CS patients overexpressing HER2 [19] [20] [21] [22] 24] , T-DM1 may represent a novel treatment option for the subset of carcinosarcoma patients harboring disease refractory to traditional salvage chemotherapy and/or unresponsive to T. The investigation of T-DM1 in patients harboring HER2/Neu gene amplified chemotherapy-resistant CS is warranted.
